NDAORALTABLETPriority Review
Approved
Dec 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
ARIMIDEX (anastrozole) by AstraZeneca is estrogens. Approved for breast cancer, metastatic breast cancer. First approved in 2008.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARIMIDEX (anastrozole) is a selective non-steroidal aromatase inhibitor that suppresses estrogen biosynthesis by blocking the enzyme that converts adrenal androgens to estrone and estradiol in postmenopausal women. It is indicated for advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy and as a breast cancer treatment. The drug works by significantly lowering serum estradiol concentrations without affecting adrenal corticosteroid or aldosterone formation.
$4MPart D
LOE ApproachingProduct is approaching loss of exclusivity with modest Part D spend of $4M (1,477 claims in 2023), signaling a contracting commercial opportunity and likely smaller, efficiency-focused team.
Mechanism of Action
estrogens. In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue…
Indications (2)
Worked on ARIMIDEX at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.